Monn J A, Valli M J, Johnson B G, Salhoff C R, Wright R A, Howe T, Bond A, Lodge D, Spangle L A, Paschal J W, Campbell J B, Griffey K, Tizzano J P, Schoepp D D
Core Technology Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
J Med Chem. 1996 Jul 19;39(15):2990-3000. doi: 10.1021/jm9601765.
The four isomers of 4-aminopyrrolidine-2,4-dicarboxylate (APDC) were prepared and evaluated for their effects at glutamate receptors in vitro. (2R,4R)-APDC (2a), an aza analog of the nonselective mGluR agonist (1S,3R)-1-aminocyclopentane-1,3-dicarboxylate (1S,3R)-ACPD, 1), was found to possess relatively high affinity for metabotropic glutamate receptors (mGluRs) (ACPD-sensitive [3H]glutamate binding IC50 = 6.49 +/- 1.21 microM) with no effects on radioligand binding to NMDA, AMPA, or kainate receptors up to 100 microM. None of the other APDC isomers showed significant mGluR binding affinity, indicating that this interaction is highly stereospecific. Both 1 and 2a were effective in decreasing forskolin-stimulated cAMP formation in the adult rat cerebral cortex (EC50 = 8.17 +/- 2.21 microM for 1; EC50 = 14.51 +/- 5.54 microM for 2a); however, while 1 was also effective in stimulating basal tritiated inositol monophosphate production in the neonatal rat cerebral cortex (EC50 = 27.7 +/- 5.2 microM), 2a (up to 100 microM) was ineffective in stimulating phosphoinositide hydrolysis in this tissue preparation, further supporting our previous observations that 2a is a highly selective agonist for mGluRs negatively coupled to adenylate cyclase. Microelectrophoretic application of either 1 or 2a to intact rat spinal neurons produced an augmentation of AMPA-induced excitation (95 +/- 10% increase for 1, 52 +/- 6% increase for 2a). Intracerebral injection of 1 (400 nmol) produced characteristic limbic seizures in mice which are not mimicked by 2a (200-1600 nmol, ic). However, the limbic seizures induced by 1 were blocked by systemically administered 2a in a dose-dependent manner (EC50 = 271 mg/kg, ip). It is concluded that (2R,4R)-APDC (2a) is a highly selective, systemically-active agonist of mGluRs negatively coupled to adenylate cyclase and that selective activation of these receptors in vivo can result in anticonvulsant effects.
制备了4-氨基吡咯烷-2,4-二羧酸酯(APDC)的四种异构体,并在体外评估了它们对谷氨酸受体的作用。(2R,4R)-APDC(2a)是一种非选择性代谢型谷氨酸受体(mGluR)激动剂(1S,3R)-1-氨基环戊烷-1,3-二羧酸酯(1S,3R)-ACPD的氮杂类似物,1)被发现对代谢型谷氨酸受体(mGluRs)具有相对较高的亲和力(ACPD敏感的[3H]谷氨酸结合IC50 = 6.49 +/- 1.21 microM),在高达100 microM时对放射性配体与NMDA、AMPA或海人藻酸受体的结合没有影响。其他APDC异构体均未显示出显著的mGluR结合亲和力,表明这种相互作用具有高度立体特异性。1和2a均可有效降低成年大鼠大脑皮层中福斯可林刺激的cAMP形成(1的EC50 = 8.17 +/- 2.21 microM;2a的EC50 = 14.51 +/- 5.54 microM);然而,虽然1在刺激新生大鼠大脑皮层中基础的氚化肌醇单磷酸产生方面也有效(EC50 = 27.7 +/- 5.2 microM),但2a(高达100 microM)在该组织制备中刺激磷酸肌醇水解无效,进一步支持了我们之前的观察结果,即2a是与腺苷酸环化酶负偶联的mGluRs的高度选择性激动剂。将1或2a微电泳施加到完整的大鼠脊髓神经元上会增强AMPA诱导的兴奋(1增加95 +/- 10%,2a增加52 +/- 6%)。脑内注射1(400 nmol)会在小鼠中产生特征性的边缘叶癫痫发作,而2a(200 - 1600 nmol,脑内注射)不会模拟这种发作。然而,1诱导的边缘叶癫痫发作会被全身给药的2a以剂量依赖性方式阻断(EC50 = 271 mg/kg,腹腔注射)。结论为(2R,4R)-APDC(2a)是与腺苷酸环化酶负偶联的mGluRs的高度选择性、全身活性激动剂,并且在体内选择性激活这些受体可产生抗惊厥作用。